Stocks and Investing
Stocks and Investing
Tue, December 20, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Joon Lee Maintained (VRNA) at Strong Buy with Increased Target to $28 on, Dec 20th, 2022
Joon Lee of Truist Securities, Maintained "Verona Pharma plc" (VRNA) at Strong Buy with Increased Target from $20 to $28 on, Dec 20th, 2022.
Joon has made no other calls on VRNA in the last 4 months.
There are 2 other peers that have a rating on VRNA. Out of the 2 peers that are also analyzing VRNA, 0 agree with Joon's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Joon
- Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $30 on, Monday, August 29th, 2022
- Yasmeen Rahimi of "Piper Sandler" Initiated at Buy and Held Target at $31 on, Friday, August 26th, 2022
Contributing Sources